Ocuphire Pharma Retained Earnings (Accumulated Deficit) 2010-2024 | IRD
Ocuphire Pharma retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Ocuphire Pharma Annual Retained Earnings (Accumulated Deficit) (Millions of US $) |
2023 |
$-81 |
2022 |
$-71 |
2021 |
$-89 |
2020 |
$-33 |
2019 |
$-8 |
2018 |
$-155 |
2017 |
$-140 |
2016 |
$-115 |
2015 |
$-106 |
2014 |
$-91 |
2013 |
$-73 |
2012 |
$-63 |
2011 |
$-57 |
2010 |
$-46 |
2009 |
$-32 |
Ocuphire Pharma Quarterly Retained Earnings (Accumulated Deficit) (Millions of US $) |
2024-06-30 |
$-96 |
2024-03-31 |
$-89 |
2023-12-31 |
$-81 |
2023-09-30 |
$-77 |
2023-06-30 |
$-82 |
2023-03-31 |
$-77 |
2022-12-31 |
$-71 |
2022-09-30 |
$-105 |
2022-06-30 |
$-101 |
2022-03-31 |
$-96 |
2021-12-31 |
$-89 |
2021-09-30 |
$-83 |
2021-06-30 |
$-79 |
2021-03-31 |
$-72 |
2020-12-31 |
$-33 |
2020-09-30 |
$-168 |
2020-06-30 |
$-166 |
2020-03-31 |
$-164 |
2019-12-31 |
$-8 |
2019-09-30 |
$-161 |
2019-06-30 |
$-159 |
2019-03-31 |
$-157 |
2018-12-31 |
$-155 |
2018-09-30 |
$-152 |
2018-06-30 |
$-146 |
2018-03-31 |
$-142 |
2017-12-31 |
$-140 |
2017-09-30 |
$-137 |
2017-06-30 |
$-136 |
2017-03-31 |
$-137 |
2016-12-31 |
$-115 |
2016-09-30 |
$-114 |
2016-06-30 |
$-112 |
2016-03-31 |
$-110 |
2015-12-31 |
$-106 |
2015-09-30 |
$-103 |
2015-06-30 |
$-99 |
2015-03-31 |
$-96 |
2014-12-31 |
$-91 |
2014-09-30 |
$-89 |
2014-06-30 |
$-87 |
2014-03-31 |
$-87 |
2013-12-31 |
$-73 |
2013-09-30 |
$-70 |
2013-06-30 |
$-68 |
2013-03-31 |
$-65 |
2012-12-31 |
$-63 |
2012-09-30 |
$-63 |
2012-06-30 |
|
2012-03-31 |
$-59 |
2011-12-31 |
$-57 |
2011-09-30 |
$-57 |
2011-06-30 |
$-56 |
2011-03-31 |
$-50 |
2010-12-31 |
$-46 |
2010-09-30 |
$-43 |
2010-06-30 |
$-41 |
2010-03-31 |
$-38 |
2009-12-31 |
$-32 |
2009-09-30 |
$-34 |
2009-06-30 |
$-33 |
2009-03-31 |
$-31 |
Sector |
Industry |
Market Cap |
Revenue |
|
|
$0.000B |
$0.000B |
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.
|